ASBMB lists four bioscience jobs across states

4 sourcesUpdated Oct 26, 20261 min read

0

ASBMB lists four bioscience jobs across states — Photo: Rakib hosan / Wikimedia Commons (Pexels)

Sponsored

The listings describe opportunities across pharmaceutical and biomedical sciences, from academic faculty appointments to a biotechnology internship. High Point University seeks a teaching-focused pharmaceutical sciences faculty member, while the University of Illinois Chicago is recruiting for a tenure-track synthetic biology position. Central Michigan University’s College of Medicine seeks an assistant professor to build an independently funded translational biomedical research program spanning fields such as cancer biology, neuroscience and immunology. Legend Biotech is offering an internship supporting laboratory testing, sample-data procedures and documentation within its analytical development team.

Sponsored

In this story:

More on this story

Back to News

Business

Artiva ends autoimmune cell therapy over durability shortfalls, will cut 94% of staff

Artiva Biotherapeutics is discontinuing its AlloNK cell therapy program for rheumatoid arthritis and other autoimmune diseases after longer-term responses fell short of its target and two patients died during trials. One death was assessed as likely related to the chemotherapy drug fludarabine, while the other was considered unrelated to treatment; Artiva is laying off about 94% of its staff and exploring strategic alternatives.

5 sources

Health

3

Total sources4

Last updatedOct 26, 2026

Does this breakdown look right?

Sponsored

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

Coverage

Sponsored

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Sponsored

Amgen Reports Combo Cuts Lung Cancer Death Risk 58%

A Phase 3 trial found that adding Amgen’s Imdelltra to AstraZeneca’s Imfinzi as maintenance therapy for extensive-stage small cell lung cancer reduced the risk of death by 58%, with median survival of 21.1 months versus 12.7 months on Imfinzi alone. The combination also delayed disease progression, though serious treatment-related side effects were more common than with Imfinzi alone.

15 sources

Sponsored

Health

Bristol Myers Reports Death in CAR-T Trial

A patient with highly active relapsing MS died of septic pneumonia 44 days after BMS zola-cel CAR-T infusion; company paused studies in September and plans to resume by 2027.

6 sources